Provided by Tiger Fintech (Singapore) Pte. Ltd.

Century Therapeutics, Inc.

0.5551
+0.00010.02%
Post-market: 0.56000.0049+0.88%16:13 EDT
Volume:214.23K
Turnover:119.67K
Market Cap:47.83M
PE:-2.14
High:0.5643
Open:0.5605
Low:0.5501
Close:0.5550
Loading ...

Century Therapeutics Inc Held Annual Stockholders Meeting Virtually

Reuters
·
17 Jun

Douglas Carr, SVP Finance & Operations, Reports Disposal of Century Therapeutics Inc Common Shares

Reuters
·
12 Jun

Brent Pfeiffenberger, President and CEO, Reports Disposal of Common Shares in Century Therapeutics Inc

Reuters
·
12 Jun

Century Therapeutics Inc to Present at EULAR 2025 Congress in Barcelona

Reuters
·
29 May

Brent Pfeiffenberger, President and CEO, Reports Disposal of Common Shares of Century Therapeutics Inc

Reuters
·
21 May

Century Therapeutics Reports Strong Q1 2025 Earnings

TIPRANKS
·
20 May

Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating

MT Newswires Live
·
19 May

Century Therapeutics Inc : Leerink Partners Cuts Target Price to $7 From $8

THOMSON REUTERS
·
19 May

The Top Corporate Board Directors -- Journal Report

Dow Jones
·
19 May

Century Therapeutics (IPSC) Receives a Hold from William Blair

TIPRANKS
·
16 May

Piper Sandler Sticks to Its Buy Rating for Century Therapeutics (IPSC)

TIPRANKS
·
16 May

Century Therapeutics Q1 Net Income USD 76.56 Million

Reuters
·
16 May

Century Therapeutics Inc - Patient Dosing Initiated in Calipso-1 Trial for Cnty-101

THOMSON REUTERS
·
16 May

Century Therapeutics Inc - Cnty-308 to Enter Ind-Enabling Studies in Mid-2025

THOMSON REUTERS
·
16 May

Century Therapeutics Q1 Collaboration Revenue USD 109.164 Million

THOMSON REUTERS
·
16 May

Century Therapeutics Inc - Clinical Data for Cnty-101 Expected by End of 2025

THOMSON REUTERS
·
16 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Century Therapeutics: Strategic Advancements and Promising Preclinical Data Justify Buy Rating

TIPRANKS
·
24 Apr

Century Therapeutics Inc : H.c. Wainwright Cuts Target Price to $2 From $5

THOMSON REUTERS
·
03 Apr

Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright

TIPRANKS
·
03 Apr